A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer.

Trial Profile

A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2015

At a glance

  • Drugs Ontuxizumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MICRO
  • Sponsors Morphotek
  • Most Recent Events

    • 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jun 2013 Trial Company changed from Morphotek to Eisai Inc, as Morphotek acquired by Eisai Inc.
    • 24 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top